Sarepta Therapeutics


Sarepta, Codiak BioSciences Team Up For Neuromuscular Disease Targeting

Sarepta Therapeutics (SRPT) has announced that it has teamed up with Codiak BioSciences to design and develop engineered exosome therapeutics to deliver gene therapy, …

Sarepta Reports Earnings Miss; But Key SRP-9001 Data Still On Track

Sarepta Therapeutics (SRPT) has reported weaker-than-expected earning results for the first quarter. Specifically, Q1 Non-GAAP EPS of -$1.

This Looks Like Just the Beginning for Sarepta Therapeutics (SRPT) Stock

There’s a new FDA-approved DMD medication on the scene. On Friday, the FDA green-lighted Sarepta Therapeutics’ (SRPT) Vyondys 53, the company’s treatment for …

Top Analyst Says Sarepta (SRPT) Stock Has More Room to Run

Christmas is over and it seems like people spent their gift money on stocks… Sarepta Therapeutics (SRPT) stock rose over 10% is the …

Cowen Reiterates Upbeat View on Sarepta Therapeutics Inc (SRPT) Amid Pipeline Collaborations

Sarepta Therapeutics Inc (NASDAQ:SRPT) just announced two Duchenne muscular dystrophy (DMD) collaborations to evaluate combotherapy with exon skipping. Sarepta will be partering with …

Sarepta: FDA’s Preliminary Guidance On DMD – Another Sign of Regulatory Flexibility, Says Roth Capital

In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target.  The analyst noted, “The FDA’s …

For Long-Term Investors We Would Recommend Buying Sarepta, Says Roth Capital

In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price …

Janney Capital Reiterates Sell On Sarepta Following CSO Termination; $13 PT

In a research report issued today, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following today’s news of the termination of …

Sarepta: We Believe That Eteplirsen Accelerated Approval Is Likely, Says Roth Capital

In a research note released yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Sarepta Therapeutics (SRPT), and a price target of $34.00.

Janney Capital Reiterates Sell On Sarepta On FDA Concerns; Sees %50 downside

In a research report issued yesterday, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following data release from …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts